Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Osimertinib + Necitumumab for Lung Cancer
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial studies the side effects and best dose of necitumumab when given with osimertinib in treating patients with EGFR-mutant non-small cell lung cancer.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.